Company news

Celularity Inc. news in 2023

Celularity Inc.'s news releases, calls and decks from 2023, newest first.

View company

Celularity Announces Commercial Biomaterial Products Receive Saudi Food and Drug Authority (SFDA) Product Classification

October 17, 2023

Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors

September 6, 2023

Celularity Announces Multi-Year Research Collaboration Services Agreement With Regeneron

August 28, 2023

Celularity Inc. Announces $3 Million Registered Direct Offering

July 26, 2023

Celularity and Verséa Ophthalmics Announce Exclusive U.S. Commercialization Agreement to Distribute Biovance® and Biovance® 3l Ocular For Ophthalmic Applications

July 26, 2023

Celularity Human Placental-Derived Advanced Biomaterials Demonstrate Superior Biocompatibility and Better Support Differentiated Cell Functions in Studies

July 17, 2023

Celularity Announces Presentation at Upcoming 7th International Conference on Orthopedics

June 28, 2023

Celularity Tissue Factor Gene Knockout of Allogeneic Stromal Cells Significantly Lowers Thrombotic Effects; Study Highlights Critical Importance of Gene Editing Capability

May 31, 2023

Celularity Announces $45 Million Purchase Order, First Middle East Private Label Agreement For Celularity’s Halal-Certified Biomaterial Products

May 22, 2023

Celularity announces $45 million purchase order, first Middle East private label agreement for Celularity's Halal-Certified biomaterial products

May 22, 2023

Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation

May 18, 2023

Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders for Celularity Branded Halal-Certified Biomaterial Products

May 9, 2023

Celularity Announces Acceptance of Presentation at 26th Annual Meeting of the American Society of Gene and Cell Therapy

April 30, 2023

Celularity Announces Clinical Data on Human Placental-Derived Unmodified Allogeneic Natural Killer Cell Therapy Candidate Cynk-001 in Adult Patients With Relapsed Refractory and Measurable Residual Disease-Positive Acute Myeloid Leukemia

April 26, 2023

Celularity’s Dr. Robert Hariri To Co-Chair The 2023 International Precision Medicine Center (IPMC) Conference “Beyond Longevity: Live 120 Like 50™”

April 11, 2023

Celularity Inc. Announces $6 Million Registered Direct Offering

April 4, 2023

Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting

April 3, 2023

Celularity Receives U.S. Food And Drug Administration (FDA) Preliminary Assessment For Celularity’s Investigational Fuse Bone Void Filler To Be Regulated As A Device By FDA’s Center For Devices And Radiological Health

April 2, 2023

Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the Gulf Cooperation Council Regions and Egypt

March 27, 2023

Celularity Announces Agreement with AD Ports Group for Exclusive Product Distribution in Various Territories in the GCC and Egypt

March 27, 2023

Celularity Receives Preliminary Assessment of Product Classification and Jurisdiction for Its Investigational Celularity Tendon Wrap (CTW) to be Regulated as a Device Within U.S. Food and Drug Administration (FDA) Center for Devices and Radiological...

January 31, 2023

Celularity Completes Strategic Review of 2023 Initiatives, Including Anticipated Biomaterials Production Ramp-Up and Pipeline Prioritization of Next-Generation Product Candidates

January 25, 2023

Celularity and CH Trading Group Announce Territory Distribution Agreement for the Middle East

January 10, 2023

Celularity and CH Trading Group Announce Product Distribution Agreement with Tamer Group to be the Exclusive Distributor for the Kingdom of Saudi Arabia

January 10, 2023

Celularity’s Placental-Derived Allogeneic Cell Therapy Provides Clinically Meaningful Benefit and Durable Biological Effect in Patients with Moderate to Severe Crohn’s Disease in Phase 1, Phase 1b/2a and Phase 1b Studies

January 5, 2023

Celularity Appoints Paul Graves as Chief Communications Officer

January 3, 2023

Decks in 2023